Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Eli Lilly and Company (LLY)’s share was trading at $765.68 as of 5 th June. LLY’s trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance.

Cramer’s bullish stance was premature as Eli Lilly fell 11.72%. Eli Lilly and Company (NYSE:LLY) remains a leader in obesity and diabetes treatment innovation, with Zepbound driving major growth ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Exchanging hands for $366, the stock is up 33% in 12 months and 16% in 2025. In the first quarter, it reported a revenue of $9.5 billion, up 10% year-over-year, and an EPS of $2.58, up 8% year ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly (NYSE:LLY) recently announced promising Phase 1 data for its folate receptor alpha antibody-drug conjugate, showcasing significant progress in oncology treatments for ovarian cancer.